Technology Platforms TEST4

NIMSB is developing cutting-edge Technology Platforms to advance medical systems biology and accelerate innovation with direct impact on human health. By applying breakthrough systems biology approaches, NIMSB aims to better understand human biology and drive medical innovation.

In collaboration with Universidade NOVA de Lisboa and the Max Delbrück Center, the institute is establishing state-of-the-art infrastructure that provides access to advanced technologies, equipment, training, and expert consultation, while supporting collaborative research and technology development.

 

Single Cell and Spatial Transcriptomics

+

State-of-the-art single-cell genomics technologies and next-generation sequencing. Consultation for experimental design, sample processing and data analysis.

Proteomics, metabolomics, lipidomics

+

Advanced mass spectrometry-based, proteomics metabolomics and lipidomics. Shotgun and targeted approaches. Support for sample preparation and data analysis.

 

Data Science and Artificial Intelligence

+

Bioinformatics tools, statistical analysis, and machine-learning methods for large datasets derived from high throughput omics approaches. Consultation for experimental design and project planning.

Human Microphysiological Systems

+

Expertise on deriving organoids from progenitors ot pluripotent stem cells, genetically modifying them and developing methods for characterization. Advise on setting up organ-on-a-chip experimental systems.

 

Clinical Science Initiative

+

Clinicians would like to intervene earlier and to understand better the development of a disease to make targeted therapeutic decisions for each person. Researchers are eager to see their discoveries reach the clinic — where they can make a real difference.​ The Clinical Science Initiative at NIMSB was created to bridge this gap. ​ ​

Our goal is to support you in accessing, understanding, and co-developing innovative technologies that respond to your clinical priorities.​ Whether you are looking to explore novel biomarkers, or integrate multi-omics approaches into patient stratification, the Clinical Science Initiative is here to collaborate and to innovate with you.

This department is being led by Dr. Cláudia Queiroga, who has 10 years of experience in the biomedical research and has worked in the clinical environment for 7 years in Portugal and internationally.​

 

         Let’s talk. Reach out to us at: csi.nimsb@unl.pt

 

 

The success of a treatment often depends on the early disease detection

Nowadays, the therapy for a disease is given to a patient once a diagnosis is made, when the disease is already manifesting symptoms. Frequently, earlier intervention leads to higher success rates.​ ​

The organism exhibits changes in homeostasis even before the disease symptoms arise.​

In addition, a deeper understanding of disease dynamics opens the door to identifying the most effective therapeutic strategies for each patient. This represents a critical window for intervention, where we propose to take action.

 

 

 

Technological platforms to foster medical innovation with real potential to improve patient care

At NIMSB, we are developing cutting-edge technological platforms designed to enhance our understanding of diseases, identify early biomarkers, track disease progression, and explore ways to intervene, guiding the body back to a state of homeostasis.

These platforms will be equipped with state-of-the-art equipment and supported by a multidisciplinary team of experts who bring deep analytical and biological insight through collaborative scientific partnerships.

 

Currently hosted at the Champalimaud Foundation Campus in Lisbon, NIMSB benefits from a leading biomedical research environment with access to world-class facilities and expertise, while building its own infrastructure toward becoming an independent Centre of Excellence.